- The investment round saw contributions from Gimv, HealthCap, Red Tree Venture Capital, and existing backers BioGeneration Ventures, M Ventures, and Brabantse Ontwikkelings Maatschappij (BOM). The funds will be The post Kivu Bioscience...
- Dubbed SPRINX-1 Study, the trial aims to assess the safety and efficacy of RXRG001 in treating radiation-induced xerostomia (RIX) [dry mouth] and hyposalivation conditions. A proprietary product created The post FDA grants IND clearance...
- Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity. The pre-clinical findings, published in Nature,...
- The acquisition will include ImmPACT’s lead product, IMPT-314, aimed at treating haematologic malignancies, such as large B-cell lymphoma. IMPT-314 is a dual-targeting CAR T-cell product candidate that is The post Lyell signs...
- The CRL, dated 22 October 2024, comes ahead of the Generic Drug User Fee Amendments of 2022 (GDUFA) goal date set for 29 October 2024. Ketamine, an essential The post FDA issues CRL to PharmaTher’s ketamine ANDA appeared first on...
- Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the...
- New research from biologists at the USC Dornsife College of Letters, Arts and Sciences reveals that mifepristone, a drug best known for its use for ending early pregnancies, might also extend lifespan. The findings could pave the way for...
- Under the terms of the agreement, TerSera will pay MacroGenics $40m upon closing. MacroGenics is also eligible for up to $35m in additional sales milestone payments. The transaction The post TerSera acquires global rights to...
- Under the contract, which extends through December 2037, Samsung Biologics will carry out the production at its biomanufacturing site in Songdo, South Korea. This latest agreement took Samsung The post Samsung Biologics signs $1.24bn...
- This recommendation paves the way for a new therapy option for adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at high risk The post Novartis gets positive...
- The acquisition bolsters AscellaHealth’s capabilities to serve international manufacturers and patients in more than 70 countries across the EU, Asia, Africa, Australia and the Americas. CHAPPER healthcare is The post AscellaHealth...
- This designation is a significant milestone for the monoclonal antibody plasma kallikrein inhibitor, which is designed to provide long-acting prevention of HAE attacks. Navenibart is effective even without The post Astria Therapeutics’...
- This partnership will see RTI, alongside investors such as Genoa Ventures and Anzu Partners, investing in Codetta Bio. RTI will also integrate Codetta Bio’s technology into research initiatives. The post RTI partners with Codetta Bio to...
- Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower...
- Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United States, according to a new study led by researchers at Yale School of Public Health and the University of...
- Since the passing of Professor Emeritus Alan Mackay-Sim AM in 2023, his ground-breaking legacy research is about to be realised with a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of...
- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo® (faricimab) for the treatment of diabetic macular edema (DME) in people from...
- The idea of using microorganisms as a source of new active ingredients is not new. Numerous drugs have already been developed on the basis of natural products from bacteria and fungi. These compete for available resources in their...
- Research published in Nature Genetics on Oct.14, by Yale Cancer Center researchers at Yale School of Medicine, found a higher concentration of a specific kind of DNA - extrachromosomal or ecDNA - in more aggressive and advanced cancers...
- Bayer has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause...
- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a variety of health conditions, including arthritis, heart conditions and other...
- Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A...
- A new study from Karolinska Institutet in Sweden and the Chinese Academy of Medical Sciences has identified an RNA molecule that is important for skin wound healing. The research, published in Nature Communications, may have implications...
- Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the prevention of childhood obesity in disadvantaged urban communities globally. Together...
- Imagine a world where your own immune cells are transformed into cancer-fighting superheroes. This is the promise of CAR-T cell therapy, a groundbreaking treatment that’s already saving lives. In this therapy, patients' own immune cells...
- AstraZeneca's supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The...
- Some proteins in the human body are easy to block with a drug; they have an obvious spot in their structure where a drug can fit, like a key in a lock. But other proteins are more difficult to target, with no clear drug-binding sites. To...
- Glioblastoma is one of the most serious brain diseases known. More than 45% of brain cancers are gliomas. Only half of glioblastoma patients respond to the FDA-approved chemotherapy Temozolomide (TMZ). Even for those patients, the cancer...
- More than one-third of adults in the United States have metabolic syndrome, a cluster of conditions that significantly raise a person's risk of heart disease, stroke, and type 2 diabetes. These conditions include high blood pressure,...
- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG announced positive 24-month data from exPDite, a Phase 1 clinical trial of bemdaneprocel, an...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22